Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio Piscaglia, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito
- Individual patient data (IPD) from the CELESTIAL trial (cabozantinib) and population-level data from the REACH-2 trial (ramucirumab) were used. To align with REACH-2, the CELESTIAL population was limited to patients who received first-line sorafenib only and had baseline serum AFP ≥ 400 ng/mL. The IPD from CELESTIAL were weighted to balance the distribution of 11 effect-modifying baseline characteristics with those of REACH-2. Overall survival (OS; primary endpoint) and progression-free survival (PFS) were compared for the CELESTIAL (matching-adjusted) and REACH-2 populations using weighted Kaplan-Meier (KM) curves and parametric (OS, Weibull; PFS, log-logistic) modeling. Rates of treatment-related adverse events (TRAEs) and TRAE-related discontinuations were also compared.
Metadaten| Verfasserangaben: | Jörg TrojanORCiDGND, Patrick Mollon, Bruno DanieleORCiDGND, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio PiscagliaORCiD, Renata ZauchaORCiD, Debashis SarkerORCiD, Ho Yeong LimORCiD, Marino VeneritoORCiDGND |
|---|
| URN: | urn:nbn:de:hebis:30:3-636457 |
|---|
| DOI: | https://doi.org/10.1007/s12325-021-01700-2 |
|---|
| ISSN: | 1865-8652 |
|---|
| Titel des übergeordneten Werkes (Englisch): | Advances in therapy |
|---|
| Verlag: | Springer Healthcare Communications |
|---|
| Verlagsort: | Tarporley |
|---|
| Dokumentart: | Wissenschaftlicher Artikel |
|---|
| Sprache: | Englisch |
|---|
| Datum der Veröffentlichung (online): | 06.04.2021 |
|---|
| Datum der Erstveröffentlichung: | 06.04.2021 |
|---|
| Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
|---|
| Datum der Freischaltung: | 23.08.2022 |
|---|
| Freies Schlagwort / Tag: | Alpha-fetoprotein (AFP); Cabozantinib; Hepatocellular carcinoma (HCC); Indirect treatment comparison (ITC); Matching-adjusted indirect comparison (MAIC); Monoclonal antibody (mAb); Ramucirumab; Tyrosine kinase inhibitor (TKI); Vascular endothelial growth factor (VEGF); second-line treatment / 2L treatment |
|---|
| Jahrgang: | 38.2021 |
|---|
| Ausgabe / Heft: | 5 |
|---|
| Seitenzahl: | 19 |
|---|
| Erste Seite: | 2472 |
|---|
| Letzte Seite: | 2490 |
|---|
| Bemerkung: | Open Access funding enabled and organized by Projekt DEAL. This study and the journal’s Rapid Service Fee was funded by Ipsen. The CELESTIAL study was sponsored by Exelixis. Ipsen was involved in the design of the study and the analysis and interpretation of the data as well as the review of the manuscript. |
|---|
| HeBIS-PPN: | 501640444 |
|---|
| Institute: | Medizin |
|---|
| DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
|---|
| Sammlungen: | Universitätspublikationen |
|---|
| Lizenz (Englisch): |  Creative Commons - Namensnennung-Nicht kommerziell 4.0 |
|---|
Creative Commons - Namensnennung-Nicht kommerziell 4.0